The Cost of Treating Human Papillomavirus-Related Oropharyngeal Cancer by Houston, Karla Smalley
Walden University
ScholarWorks
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral StudiesCollection
2019




Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Medicine and Health Sciences Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been



















has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  




Dr. Cheryl Anderson, Committee Chairperson, Health Sciences Faculty 
Dr. Ronald Hudak, Committee Member, Health Sciences Faculty 






Chief Academic Officer 












The Cost of Treating Human Papillomavirus-Related Oropharyngeal Cancer 
by 
Karla Smalley Houston 
 
MHA, University of St. Francis, 2014 
BS, University of St. Francis, 2007 
 
 
Doctoral Study Submitted in Partial Fulfillment 
of the Requirements for the Degree of 









Human papillomavirus (HPV) is a sexually transmitted infection contributing to 70% of 
oropharyngeal cancers in the United States. The incidence of HPV-related oropharyngeal 
cancers is greater in Kentucky’s population than in any other state. Research has 
demonstrated the cost of treating oropharyngeal cancer on a national level, but little 
information exists as to state-specific costs. The purpose of this quantitative study was to 
examine radiation therapy costs for treating HPV-related oropharyngeal cancer in 
Kentucky in relation to age, gender, race, and insurance. A theory by Aday and Andersen 
was applied to explain the relationship between the independent and dependent variables. 
Cluster sampling was used to randomly select 130 de-identified men and women age 40-
65 years who had been diagnosed with oropharyngeal cancer. The data were collected 
from an existing database. The study used descriptive analysis with correlational, 
longitudinal data to examine the relationship of categorical and continuous variables. The 
mean cost for radiation therapy treatment was $123,629.14 (SD= $58,697.36). The 
multiple regression indicated that the null hypothesis was accepted showing that the 
independent variables were not statistically significant predictors of the z Score of Cost 
Difference [F (4,122) = 0.972, p = 0.425]. The results showed no significant independent 
predictor variables (p > 0.05); gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378, 
p = 0.171], insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230, 
p = 0.818]).  The results may contribute to positive social change in the development of 
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Section 1: Foundation of the Study 
Introduction 
Head and neck cancer is a serious disease that affects many people worldwide. 
Head and neck cancers account for over 333,000 deaths each year globally and over 
11,000 deaths in the United States annually (Jones, Fekrazad, & Bauman, 2013). Cancers 
originating from the paranasal sinuses, nasal cavity, salivary glands, oral cavity, 
oropharynx, nasopharynx, hypopharynx, and larynx are referred to as head and neck 
cancers (Denson, Janitz, Brame, & Campbell, 2016; Howard & Chung, 2012; Maasland, 
van de Brandt, Kremer, Goldbohm, & Schouten, 2014). Oropharyngeal cancer is a form 
of head and neck cancer that forms in the cells of tissue of the middle part of the throat 
(pharynx; National Cancer Institute, n.d., 2015). Oropharyngeal cancer rates are 
increasing, with data suggesting that human papillomavirus (HPV) may be an important 
causal reason for this rise (D’Souza & Dempsey, 2011). It is estimated that 20 million 
people are currently infected with HPV (Lewis, Kang, Levine, & Maghami, 2015). 
Potentially 6.2 million new cases will occur annually worldwide in the coming years 
(Lewis et al., 2015). Oropharyngeal cancer is the second most common HPV-associated 
cancer deserving attention for future interventions (Centers for Disease Control and 
Prevention [CDC], 2017). The impact of HPV on oropharyngeal cancer is of concern. 
HPV-related oropharyngeal cancer is increasing worldwide, affecting people at a younger 
age. 
The link between HPV and oropharyngeal cancers is currently being researched. 
Approximately 30,000 people worldwide with oropharyngeal cancers are also diagnosed 
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with HPV, which is detected in 25% of all head and neck cancers in the United States 
(D’Souza & Dempsey, 2011). HPV contributes to 70% of oropharyngeal cancers in the 
United States (Lewis et al., 2015). The population with oropharyngeal cancers is younger 
than those with tobacco-mediated cancers (Lewis et al., 2015). Historically, 
oropharyngeal cancers were diagnosed in older males who abused tobacco and alcohol, 
but currently oral cancer is affecting those under the age of 40 years (Lewis et al., 2015). 
The exact incidence of HPV-positive oropharyngeal cancer is unknown and could be 
misrepresented because current practice does not support testing all oropharyngeal 
cancers for HPV status (Boggs, 2015). HPV as a risk factor alone may not be sufficient to 
cause oropharyngeal cancers. More research is needed to investigate whether other risk 
factors along with HPV cause oropharyngeal cancers. Although research has occurred 
worldwide on this topic, little research has been completed using state-specific data in the 
United States. Kentucky has some of the highest HPV-related cancer rates in the nation, 
including rates of oropharyngeal cancer (Kaprowy, 2012). Therefore, the problem that I 
explored in this study was the impact of costs associated with treating oropharyngeal 
cancer in Kentucky on health systems. Addressing HPV through studies such as this one 
may help inform efforts to lower the number of HPV-related oropharyngeal cancers and 
reduce associated cost burdens on health care systems. 
Kentucky’s population demonstrates a higher incidence of HPV-related 
oropharyngeal cancer compared to other states (CDC, 2017). Understanding the burden 
of HPV and oropharyngeal cancer within this population is necessary. The data in this 
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study may provide information on the economic burden of HPV-related oropharyngeal 
cancer. 
Problem Statement 
Cancer is a major cost driver in the U.S. health care system. In 2017 in the United 
States, 1.7 million new cancer cases were diagnosed (American Cancer Society [ACS], 
2017). The economic impact of cancers is significant. In 2014, $87.8 billion was spent on 
cancer in the United States. (ACS, 2017). Health care costs have risen to approximately 
$2 trillion, with the costs of cancer representing $200 billion (Lyman, 2017). Specific 
types of cancers, such as oropharyngeal cancer, have a unique impact upon the U.S. 
health system. The 5-year invasive incidence rates for HPV-related oropharyngeal 
cancers are 11.0 per 100,000 persons in the United States and 13.6 per 100,000 persons in 
Kentucky (Kentucky Cancer Registry [KCR], 2016). The mortality rates are 2.5 per 
100,000 persons for the U.S. and 2.8 per 100,000 persons for Kentucky (KCR, 2016). 
These statistics could provide data for policy recommendations for the Kentucky 
population. 
Purpose 
The purpose of this study was to use secondary data to examine the costs of 
radiation therapy for treating HPV-related oropharyngeal cancer based on age, gender, 
race, HPV status, and insurance in Kentucky. Twenty-five percent of Kentucky’s adult 
population consists of smokers (AE&A, 2017). Tobacco use is linked to 85% of 
oropharyngeal cancers (AE&A, 2017). The primary risk factor for oropharyngeal cancer 
is oral HPV (Osazuwa-Peters et al., 2015). Oral HPV is considered a sexually transmitted 
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disease (AE&A, 2017). The disease has been linked to sexual behaviors such as early age 
at coitus, multiple partners, oral sex, and kissing (Osazuwa-Peters et al., 2015). Males 
and Blacks have a higher incidence of oropharyngeal cancer compared to females and 
Whites. Oropharyngeal cancer has not been recognized as an indicator for HPV 
vaccination (Ward, Mehta, & Moore, 2016). The link between HPV and oropharyngeal 
cancer could present health care organizations and health care leaders in Kentucky with 
opportunities to address cost drivers such as HPV in cancer diagnoses. 
Research Question 
RQ. Is there a significant predictive relationship between patient gender, age, 
insurance type, and race and the increased cost of radiation therapy associated with HPV-
related oropharyngeal cancer in Kentucky? 
H01:  There is no significant predictive relationship between patient gender, age, 
insurance type, and race and the increased cost of radiation therapy 
associated with HPV-related oropharyngeal cancer in Kentucky. 
Ha1: There is a significant predictive relationship between patient gender, age, 
insurance type, and race and the increased cost of radiation therapy 
associated with HPV-related oropharyngeal cancer in Kentucky. 
The secondary data types considered to answer the research question were 
deidentified data on newly diagnosed patients with oropharyngeal cancer at a cancer 
center in Louisville, Kentucky. Data extracted for this study were from 2010 to 2016. 
These years were chosen because data on HPV-associated oropharyngeal cancer were not 
collected before 2009. During the period from 2010 to 2016, there were 1,654 newly 
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diagnosed head and neck cancers in this population, and the number of people diagnosed 
with oropharyngeal cancers was 628. Of the 628 cases of oropharyngeal cancer that were 
diagnosed, 208 cancers were associated with HPV. For data on costs, I used previous 
literature and Current Procedural Terminology (CPT) codes from cancer center electronic 
medical records. 
Theoretical Foundation for the Study 
The framework for this study was based on a theory by Aday and Andersen 
(1974) that provides a causal structure for utilization and cost associated with health 
services. Aday and Andersen’s theory may be used to explain costs related to 
predisposing factors, enabling factors, and need factors. The independent variables for 
this study were the predisposing factors of age, race, gender, and HPV status; the 
enabling factor of insurance; and the needs factor of oropharyngeal cancer. The 
dependent variable was cost. Different versions of the Aday and Andersen model have 
been used in studies on predisposing factors such as age, marital status, gender/sex, 
education, ethnicity/nativity, and employment status (Babitsch, Gohl, & von Lengeke, 
2012). Enabling factors in these studies have included income/financial situation, health 
insurance, source of care/family doctor, and availability of medical services/inpatient and 
outpatient care facilities (Babitsch et al., 2012). Need factors have included health status, 
self-reported/perceived health, diabetes, depression, hypertension, heart disease, and 
cancer (Babitsch et al., 2012).  
Kepka, Smith, Zeruto, & Yabroff (2014) presented a study using Aday and 
Andersen’s theory as a framework to describe how healthcare utilization is influenced by 
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health policies, delivery systems, and population characteristics as they impact access to 
health services. The independent variable in the study by Kepka et al. was medical 
provider. The dependent variables were cancer screening, HPV vaccination, and cancer 
prevention recommendations. The characteristics used in this study were similar to those 
used in my study; such as insurance, age, and health status in the utilization of health 
care. The findings suggested that access to primary care providers was a factor related to 
health outcome. For this study, a search of literature from previous studies involving 
HPV and oropharyngeal cancer was performed to examine the costs of the disease. The 
relationship between HPV and oropharyngeal cancer may provide insight on 
interventions for these populations. 
Nature of the Study 
The study was quantitative in nature and used the Aday and Andersen theory as 
the framework to examine the link between HPV and radiation therapy cost associated 
with HPV-related oropharyngeal cancer. Cluster sampling was used to randomly select 
participants from the head and neck database. The samples were composed of 130 men 
and women aged 40-65 years who had been diagnosed with oral cancer. The G*Power 
analysis program was used to determine the sample size. The samples included all men 
and women diagnosed with HPV-related oropharyngeal cancer. The CDC (2012b) 
provided age-based statistics regarding oropharyngeal cancer diagnosis: 62 years old 
among women and 59 years old among men. The study assessed the possible relationship 
between HPV and the cost of HPV-related oropharyngeal cancer among populations 
based on age, gender, insurance, and race in Kentucky. If there is a correlation between 
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HPV and increased costs associated with HPV and oropharyngeal cancer, testing and 
prevention efforts may be addressed. 
Deidentified data were used to evaluate the possible relationship between HPV 
and the cost of HPV-related oropharyngeal cancers. The study used descriptive analysis 
with correlational, longitudinal data collected over time to examine the relationship of 
categorical variables (gender, race, HPV status, insurance) and continuous variable (age) 
for oropharyngeal cancer using SPSS Statistics. Logistics regression was used for the 
continuous and categorical variables. Multistage random sampling was used to help 
generalize to the population. Characteristics used to stratify the population included age, 
gender, race, insurance, and HPV status from the head and neck database gathered from 
multidisciplinary clinics. 
Literature Search Strategy 
I searched literature on the prevalence of oropharyngeal cancer and HPV in 
Kentucky. I reviewed existing literature on oropharyngeal cancer associated with HPV 
based on age, gender, race, and insurance status. Interventions based on knowledge of 
HPV as a contributing factor could lower oropharyngeal cancer rates and reduce the 
burden of associated costs on health care systems. 
I conducted a review of current literature, using the Walden University Library to 
access the CINAHL, PubMed, ProQuest, Science Direct, and MedLine databases. Google 
Scholar was used to search for literature from the CDC, ACS, National Cancer Database 
(NCDB), and National Cancer Institute, Surveillance, Epidemiology, and End Results 
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Program (SEER). Key terms used in the literature search included oropharyngeal cancer, 
HPV, health care costs, and oropharyngeal cancer and HPV. 
Literature Review 
The purpose of this literature review is to summarize the relationship between the 
independent variables (age, gender, race, and insurance) and the dependent variable (cost) 
associated with HPV-related oropharyngeal cancer. The research problem was that HPV-
related oropharyngeal cancer poses an economic burden on health systems in Kentucky. 
Based on a review of literature addressing the cost of treating HPV-related oropharyngeal 
cancer and relevant factors; the following sections focus on the topics of HPV 
prevalence, oropharyngeal cancer, age, gender, race, insurance, and cost. 
HPV Prevalence 
HPV is the most commonly diagnosed sexually transmitted disease in the United 
States (Haddad, 2017). HPV is a DNA virus that infects skin and wet surfaces of the body 
(Mount Sinai Hospital [MSH], 2017). There are more than 100 types of HPV and at least 
40 HPV types that affect the genital areas. Some cause genital warts and are low risk, 
whereas high-risk types cause cervical and other genital cancers. An estimated 492,800 
cervical cancers are caused by HPV each year (D’Souza & Dempsey, 2011). HPV 16, 18, 
31, and 33 are high-risk genotypes for cervical cancer (Haddad, 2017), and of these high-
risk types, HPV 16 accounts for 90% of oral infections (Lewis et al., 2015). Most 
sexually active men and women will acquire HPV in their lifetime. HPV, known to cause 
cervical cancer, is now being linked to an increase in oropharyngeal cancers. 
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According to the National Cancer Institute (NCI, 2017), cancers of the tonsil or 
base of tongue are affecting people who are usually at low risk of HPV-related infections. 
The epidemiology of oral HPV infection is not quite understood, even though the virus 
has been known to cause cancers of the cervical, vulvar, penile, and ano-genital areas 
(Osazuwa-Peters et al., 2015). The belief is that there is an increase in people engaging in 
sexual activity with multiple partners and an increase in oral sex practices resulting in 
contracting HPV in the neck region (Osazuwa-Peters et al., 2015). 
Approximately 39,000 newly diagnosed HPV-related cancers were seen between 
2008 and 2012 in the United States (CDC, 2016). The most common were cervical 
carcinomas and oropharyngeal carcinomas. Of the 39,000 cancers in the United.States, 
approximately 30,700 could be associated with HPV (Viens et al., 2016). The CDC 
reported that Utah has the lowest rate of HPV-related cancers, with 7.5 cases per 100,000 
persons, while Kentucky has the highest, with 14.7 cases per 100,000 persons (CDC, 
2016). A study was conducted in Appalachia showing higher incidence rates for HPV-
related cancers for males and females than non- Appalachia males and females (Reiter et 
al., 2013). The study suggests that there exist disparities beyond cervical incidence rates, 
including oral cavity and pharyngeal cancers.  
Oropharyngeal Cancer 
Cancers of the oropharynx are on the rise. According to the ACS (2016), oral 
cancer is the sixth most common form of cancer in the United States. Areas affected by 
oral cancers include the nasal cavity, sinuses, lips, mouth, thyroid glands, salivary glands, 
larynx, and pharynx, which are divided into the nasopharynx, oropharynx, and 
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hypopharynx (CDC, 2017). In 2013 in the United States, 41,717 people (29,693 men and 
12,024 women) were diagnosed with oral cancers (CDC, 2017). Approximately 8,850 
people (6,227 men and 2,523 women) died from these diseases (CDC, 2017). 
More than 90% of oral and oropharyngeal cancers are squamous cell carcinomas. 
The most common locations for these cancers are the tongue, tonsils, oropharynx, gums, 
and floor of the mouth. The risk factors for oropharyngeal cancer are tobacco use, 
alcohol, prolonged sun exposure, and HPV. Cancers of the tonsils and base of tongue 
have become more common due to HPV exposure. Sexual activity, including oral sex, is 
the most common way to get HPV. 
A U.S. study reported that oral sex was common among women and men but was 
most common among people 30-49 years old (D’Souza & Dempsey, 2011). Oral sex was 
reported by 86% of 30- to 40-year-old men, 74% of men aged 50-69 years, and 62% of 
men aged 70 years or older, compared to 82%, 77%, and 43% of women aged 30-49 
years, 50-69 years, and 70 years or older, respectively (D’Souza & Dempsey, 2011; 
Herbenick et al., 2010). The progression from HPV infection to malignancy can take up 
to 10 years (D’Souza & Dempsey, 2011). A change is sexual behavior could explain the 
increase in oral cancers several decades later. 
A study conducted in Oklahoma examined trends in oral cancer and 
oropharyngeal cancer. The study used data from the Oklahoma Central Cancer Registry 
and Surveillance, Epidemiology, and End Results program to compare people diagnosed 
from 1997-1999 to those diagnosed from 2010-2012 (Denson et al., 2016). The study 
observed differences by race, gender, and age. The findings showed an increase in 
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oropharyngeal cancer over time. There was an age-adjusted increase in oropharyngeal 
cancer incidence from 3.2 (95% CI: 2.6, 3.8) per 100,000 in 1997 to 5.1 (95% CI: 4.4, 
5.8) per 100,000 in 2012 (Denson et al., 2016). The explanation for the increase in 
oropharyngeal cancer rates was an increase in HPV prevalence.  
Race 
Rates of human papillomavirus oropharyngeal cancer vary by race. Cole, Polfus, 
and Peters (2012) provided evidence that HPV-associated cancers disproportionately 
affect certain age, sex, and race/ethnicity groups. Non-Hispanic Blacks present with 
higher incidence of oropharyngeal cancers compared to women and individuals of other 
races (Cole et al., 2012). White men have been reported as having the highest rate of 
cancers of the oral cavity, followed by Black men (CDC, 2017). There was a significant 
increase in HPV-associated neck cancers, whereas non-HPV-associated neck cancers 
declined (Cole et al., 2012). The results indicated that Non-Hispanic Whites and 
Hispanics represented with greater increases in incidence for HPV-associated sites, 
whereas incidence declined among non-Hispanic Blacks independent of HPV association 
(Cole et al., 2012). 
Human papillomavirus oropharyngeal cancer affects more Whites (21-64%) than 
Blacks (0-35%; Rettig, Ponce Keiss, & Fakhry, 2015). Findings from a population-based 
study indicated that Whites are more likely to perform oral sex, have more sexual 
partners, and engage in sex at a younger age than Blacks (Rettig et al., 2015). Although 
oral infections were higher among Blacks in the United .States (10.5%) compared to 
Whites (6.5%, p = 0.06), there was no significant difference in the prevalence of 
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infections by race (Rettig et al., 2015). Only oral HPV among men showed higher 
incidence in Whites. 
Age 
Oropharyngeal cancer has been proven to be more prevalent in younger adult 
populations without histories of drinking and smoking (Minassian, 2014). A cross-
sectional study of men and women 14 to 69 years old found that HPV DNA prevalence in 
oral exfoliated cells was 6.9%, and the prevalence of HPV 16 was 1% (Jones et al., 
2013). HPV-positive oropharyngeal cancer patients are younger when compared to HPV-
negative oropharyngeal cancer patients. The median age was 57 years for HPV-positive 
patients, compared to 61 years for HPV-negative patients (O’Sullivan et al., 2016). The 
population-level burden is currently unknown for HPV-related oropharyngeal cancer. 
This may have important implications for cancer prevention through HPV vaccination 
and education. 
The National Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER) population study examined data from 2002 to 2012. It included 149,301 head and 
neck cancer cases, with 37,965 being oropharyngeal cancer (Mourad et al., 2017). The 
study concluded that patients under 60 years of age made up 59.2% of HPV-related 
cancer (Mourad et al., 2017). 
Gender 
Twice as many men as women are diagnosed with oropharyngeal cancers (CDC, 
2017). The SEER population study of data from 2002 to 2012 concluded that the male-to-
female ratio was 4:1 for HPV-related oropharyngeal cancer. The HPV-related 
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oropharyngeal cancer rate for men increased by 2.89% per year compared to an 
insignificant increase of 0.57% for women (Mourad et al., 2017). A Portugal study 
reported an increase of 3.5 annual percentage change (APC) in men with oropharyngeal 
cancer (Mourad et al., 2017). Korea reported similar results with an APC of 2.65% 
increase for men (Mourad et al., 2017). The findings suggest that more men are 
developing HPV-related oropharyngeal cancer, potentially skewing gender distribution. 
In contrast, a study in England found increased incidence in men and women (47.1% and 
37.5%, respectively; Mourad et al., 2017).  
Human papillomavirus is associated with an increase in oropharyngeal cancer in 
the United States and other countries. Combes, Chen, and Franceshi (2014) assessed the 
results of 63 studies reporting oropharyngeal cancer data by gender. The United States 
had the highest male to female ratio of HPV oropharyngeal cancer, while Asia and some 
European countries were the lowest (Combes et al., 2014). HPV oropharyngeal cancer for 
men was 65.8% in North America and 28.9% in Asia (Combes et al., 2014). In contrast, 
Asian women presented highest (61.5%) for HPV oropharyngeal cancer. The 
confirmation that HPV oropharyngeal cancer data differ by gender is relevant. 
Insurance 
The Kentucky Department of Insurance regulates the market that includes 
Medicare, Medicaid, commercial insurers, and payment/reimbursement. Kentucky ranks 
18th nationally in access to health care, and 9.8% of Kentucky’s population is uninsured 
(Bowling, 2016). Kentucky was one of two states to increase Medicaid coverage 
following passage of the Affordable Care Act. Approximately 268,000 people gained 
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coverage; the majority were adults 19-64 years old, with Medicaid coverage increasing 
by 80% (Bowling, 2016). In 2017, Kentucky’s state-based exchange transitioned to a 
federal exchange. 
Cancer prevention and screening services are covered under the Affordable Care 
Act. Screening services for breast, cervical, colon, lung, and HPV vaccinations for males 
and females 11-26 years of age are covered in Kentucky. Routine screening for head and 
neck cancer is not covered. A study conducted on patients with neck cancer showed that 
Medicaid patients presented with advanced cancer and higher rates of treatment delays 
compared to non-Medicaid patients (Naghavi et al., 2016). Oropharyngeal cancer 
treatment poses a significant cost for Medicaid, suggesting that early detection may 
reduce the economic burden of the disease. 
Costs 
High treatment costs for oropharyngeal cancer often involve a combination of 
surgery, radiation, and chemotherapy. A review of 299 patients diagnosed with 
oropharyngeal cancer between 2011 and 2015 revealed 72 patients available for 
evaluation to determine costs associated with treatment (Pinheiro & Krama, 2016). Forty-
two patients were treated with surgery and twenty-nine patients were treated without 
surgery. Patients treated with surgery alone relative to no surgery had the lowest cost 
($38,462, $83,222; Pinheiro & Krama, 2016). Patients who had surgery followed by 
chemotherapy/radiation had similar costs compared to patients treated with primary 
chemotherapy/radiation ($84,598 vs. $83,222; Pinheiro & Krama, 2016). 
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A 2-year study in Texas found the cost of treating oropharyngeal cancer to be 
$139,749. The data were extracted from Truven MarketScan Commercial Claims and 
Encounter Database from 2011-2004. The data included 467 patients with oropharyngeal 
cancer and a control group of 467 noncancer patients. Age, comorbidity, mental health, 
prediagnostic cost, and time were predictors of cost (Cavallo, 2017). The findings 
showed that the cost of care for oropharyngeal cancer was higher than in previous 
studies. The mean cost was $6,693 for people with cancer and $870 for those without 
cancer (Cavallo, 2017). The majority of the cost was from outpatient services ($106,604); 
inpatient costs and drug costs were $42,341 and $3,550, respectively (Cavallo, 2017). 
Ward et al. (2016) provided information on costs associated with HPV-related 
oropharyngeal cancer. With 13,000 new cases annually, the estimated mean lifetime cost 
per new case of HPV-related cancer is $43,000, which translates to a total cost for the 
United States of $306 million (Ward et al., 2016). By vaccinating boys and men, it would 
be possible to prevent 5,416 and 43,168 cases of HPV-related oropharyngeal cancer in 50 
and 100 years, respectively, due to the latent period between HPV infection and the 
development of oropharyngeal cancer (Ward et al., 2016). The costs to vaccinate for HPV 
are predicted to be below the $50,000/quality-adjusted life year threshold that determines 
the cost-effectiveness of public health initiatives (Ward et al., 2016). 
Chesson et al. (2012) provided information on direct costs attributed to HPV. 
Their report provided estimated annual costs for screening, follow-up care, and treatment. 
Cervical and oropharyngeal cancers account for $1 billion of total costs for HPV-related 
cancers (Chesson et al., 2012). A study in France provided by Borget, Abramowitz, & 
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Mathevet (2011) provided data on the economic burden of HPV-associated cancers. The 
study assessed the annual costs of cancers of the vulva, vagina, anus, penis, and head and 
neck. The costs for men were $107.2 million caused by head and neck cancers. The costs 
for women were $83.9 million due to cervical cancer. This information is important to 
consider for evaluating HPV vaccines for men and women. 
A retrospective study consisting of 365 patients 20 years or older assessed median 
monthly costs as follows: $2,199 for diagnosis, $4,161 for treatment, $6,614 for end-of-
life care, and median total cost $110,793 (Reveles, Reveles, Frei, Frei, & Koeller, 2017). 
Costs were driven by outpatient costs (23%), inpatient costs (18%), and radiation therapy 
(16%; Reveles et al., 2017). 
Data offered by Vanderpool (2016) on Kentucky’s oropharyngeal costs and HPV 
vaccination rates suggest that the United States spends approximately $8 billion annually 
on HPV-associated disease (Vanderpool, 2016). The average number of oropharyngeal 
cancers in the United States each year is 12,638 for males and 3,100 for females (CDC, 
2012a; Vanderpool, 2016). The number of oropharyngeal cancers caused by HPV each 
year in the United States is 9,100 for males and 2,000 for females (CDC, 2012a; 
Vanderpool, 2016). The 5-year invasive incidence rate is 11.0 for the United States and 
13.6 for Kentucky. The mortality rates are 2.5 for the United States and 2.8 for Kentucky. 
These statistics could provide data for policy recommendations for the Kentucky 
population. 
Definition of Terms 
Terms operationalized by this study include the following: 
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Cancer center: Cancer centers carry out laboratory, clinical, and population-based 
research. Although most cancer centers provide care for people with cancer, some only 
conduct laboratory research (American Society for Clinical Oncology [ASCO], 2017). 
Carcinoma: Cancer that begins in the skin or in tissues that line or cover body 
organs (Medicine Net, 2018). 
Human papillomavirus (HPV): An infection caused by a DNA virus that is spread 
through sexual contact and is associated with a range of diseases and cancers (NCI, 
2015). 
Medicaid: Medicaid provides health coverage to millions of Americans, including 
eligible low-income adults, children, pregnant women, elderly adults, and people with 
disabilities. Medicaid is administered by states according to federal requirements. The 
program is funded jointly by states and the federal government (Centers for Medicare and 
Medicaid Services [CMS], 2018). 
Medicare: Medicare is a health insurance program for people 65 years of age or 
older, people under age 65 with certain disabilities, and people of all ages with end-stage 
renal disease (permanent kidney failure requiring dialysis or a kidney transplant; CMS, 
2018). 
Oropharyngeal cancer: Oropharyngeal cancer is a form of head and neck cancer 
that forms in the cells of tissue of the middle part of the throat (pharynx; NCI, n.d., 2015). 
Race: A category whereby an individual or group is classified according to 




Radiation therapy: Radiation therapy is a type of cancer treatment that uses 
beams of intense energy to kill cancer cells (Mayo Clinic, 2018).  
Sexually transmitted diseases: Diseases that are passed from one person to 
another through intimate physical contact and sexual activity, including vaginal, oral, and 
anal sex (CDC, 2017). 
Assumptions 
In this study, I relied on the following assumptions: The head and neck database 
on Kentucky residents included the variables needed to complete the study. I assumed 
that there would be enough participants; that all the data is complete; that access would 
not be difficult.  
Limitations 
This study is limited to existing data collected from a Louisville, Kentucky cancer 
center between 2010 and 2016. Age, gender, race, insurance, and HPV were the variables 
used for the study. Other variables that are associated with oropharyngeal cancer, such as 
smoking and drinking were not considered. 
Delimitations 
I used data from a cancer center in Louisville, Kentucky. No other oropharyngeal 
cancer data was used. Men and women in the study are 40-65 years of age. The 
participants are residents of Kentucky diagnosed with HPV related oropharyngeal cancer 




The significance of this study was to examine the possibility that HPV 
vaccination may impact cost resulting from HPV related oropharyngeal cancers in 
Kentucky. Oropharyngeal cancer treatment therapies used to treat oropharyngeal cancer 
can result in substantial cost to our healthcare system (Ward et al., 2016). The 
oropharynx is the most common site for HPV infection (OCF, 2017). Oral cancers that 
were commonly associated with older males and alcohol consumption are now affecting 
younger populations regardless of alcohol or tobacco use (OCF, 2017). By 2020, HPV 
oral pharyngeal squamous cell carcinoma is projected to outnumber HPV mediated 
cervical cancer in the United States (Lewis et al., 2015).   
Summary 
Oropharyngeal cancer rates are increasing with data suggesting that Human 
Papillomavirus (HPV) may be an important causal reason for this rise (D’Souza & 
Dempsey, 2012). Oropharyngeal cancers were diagnosed in older males who abuse 
tobacco and alcohol, but currently oral cancer is affecting those under the age of 40 
(Lewis et al., 2015). Kentucky has some of the highest HPV related cancer rates in the 
nation; including oropharyngeal cancer (AE&A, 2017). Therefore, the problem was to 
examine the burden of costs associated with treating oropharyngeal cancer in Kentucky. 
This study could contribute to a positive social change by addressing HPV and the impact 




Human Papillomavirus that is associated with oropharyngeal cancer is closely 
associated with cervical cancer. Ceravix is an approved vaccine that protects against HPV 
16. The vaccine was developed to reduce the incidence of ano-genital neoplasms and may 
be possible to reduce the incidence of HPV related oral cancers. By 2020, HPV oral 
pharyngeal squamous cell carcinoma is projected to outnumber HPV mediated cervical 
cancer in the United States (Lewis et al., 2015).  Addressing human papillomavirus as a 
contributing factor in the increase of oropharyngeal cancers may develop interventions 




Section 2: Research Design and Data Collection 
Introduction 
The cost associated with radiation therapy treatments for HPV-related 
oropharyngeal cancer is substantial. The purpose of this study was to use secondary data 
to determine the impact that age, gender, race, and insurance have on the cost of treating 
HPV-related oropharyngeal cancer. Section 2 contains explanations of the research 
design and data collection method used to examine HPV-related oropharyngeal cancer 
costs. In this section, I address the research design, rationale, methodology, data analysis 
plan, threats to validity, and ethical procedures in detail. 
Research Design and Rationale 
For this quantitative research study, I used a head and neck cancer database to 
determine the radiation therapy cost for HPV-related oropharyngeal cancer based on age, 
gender, race, and insurance. This methodology was appropriate for testing my theory by 
examining the relationship among variables. Creswell (2009) stated that quantitative 
research design can be used to evaluate relationships among variables. I conducted a 
correlational, longitudinal descriptive analysis to evaluate the possible relationship 
between HPV-related oropharyngeal cancers and the cost of treating these cancers based 
on age, gender, race, and insurance. Retrospective data were used from a head and neck 
cancer database. All data were deidentified to avoid ethical concerns and to protect 
confidentiality.  
In this study, the data allowed for evaluating the extent to which factors affected 
the cost of treatments. The independent variables were age, gender, race, and insurance. 
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The dependent variable was cost. The use of quantitative methodology was appropriate to 
assess the cost of radiation therapy treatments because it provided information about the 
relationships between the variables. 
There were no resource constraints for this study. There were time constraints 
affecting data collection. No data collection took place prior to Institutional Review 
Board (IRB) approval. 
For this study, there was one research question and two hypotheses: 
RQ: Is there a significant predictive relationship between patient age, gender, 
insurance type, and race and the increased cost of radiation therapy associated with HPV-
related oropharyngeal cancer in Kentucky? 
H1:  There is no significant predictive relationship between patient age, gender, 
insurance type, and race and the increased cost of radiation therapy 
associated with HPV-related oropharyngeal cancer in Kentucky. 
H0:  There is a significant predictive relationship between patient age, gender, 
insurance type, and race and the increased cost of radiation therapy 
associated with HPV-related oropharyngeal cancer in Kentucky. 
Methodology 
Secondary Dataset Management 
A secondary database from a regional cancer center was used to complete this 
study. The data came from a head and neck cancer database. All participants whose 
information was included in these data were HPV positive and had been diagnosed with 
oropharyngeal cancer between the ages of 40 and 65. I was granted permission to access 
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the dataset from the University Medical Center (UMC) Research Office. Researchers 
using the database, which contains protected health information, must read and agree to 
all terms and conditions relating to the dataset. Consent to use the data was given by the 
UMC Research Office. 
Sampling and Sampling Procedure 
The data were produced from a dataset using a stratified sampling technique. The 
multiple strata included HPV, diagnosis of head and neck cancer of the oropharynx, age, 
gender, race, insurance, and radiation treatments.  
Sample and Population Size 
            In total, data for 1,654 cases of head and neck cancers were collected. Of the 
1,654 head and neck cancers, 628 were diagnosed with oropharyngeal cancer. Out of the 
628 cases, 208 tested positive for HPV or p16. The final sample size of 130 participants 
was determined by G*Power analysis. A systematic random sampling technique was used 
to select the participants based on strata, with equal opportunity of selection within each 
stratum. 
Inclusion and Exclusion Criteria 
All participants in this data collection were HPV positive and had been diagnosed 
with oropharyngeal cancer between the ages of 40 and 65. The original data included all 
head and neck cancers regardless of HPV status or age. Participants who were under the 
age of 40 years, over the age of 65 years, and/or HPV negative were excluded. 
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Data Collection Tools 
The participants were seen in a multidisciplinary clinic with a positive diagnosis 
of head and neck cancer. The data were driven by physicians. The data were assessed 
using the National Comprehensive Cancer Network (NCCN) guidelines for the head and 
neck cancer workup. The original data included name, medical record number, 
consultation, pathology, HPV status, stage, treatment, protocol, vitals, treatment start and 
completion date, ears, nose, and throat (ENT) specialist referral, expiration date, and 
comments. Testing for HPV and p16 is done as part of the workup that determines 
treatment and prognosis. Data have been collected from 2009 to the present to assess the 
status, diagnosis, and treatment regimens of participants.  
For this study, the participants were selected from the head and neck cancer 
database. The data collected for participants that met the selection criteria were from 
2010 to 2016. Data were collected on every head and neck cancer patient seen in the head 
and neck clinic. The patients had a positive biopsy for cancer diagnosis. 
The data collected came from the outpatient electronic medical record (EMR). For 
data collection purposes, information was put into a deidentified format with a master list 
stored in a separate, password-protected location. 
Justification for the Effect Size, Alpha Level, and Power Level 
The minimum effect size was chosen to allow for greater external validity due to 
this being a stratified multistage cluster study. To reduce Type 1 error, the alpha level 
was 0.3, with a power level of 80 to reduce Type 2 error. 
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Proposed Data Analysis Plan 
I planned to conduct a simple descriptive analysis. Bivariate and multivariate 
analyses were used to identify associations between the dependent and independent 
variables. A multiple regression analysis was used to reduce statistical errors. I developed 
the research question using Aday and Anderson’s theory as a guide for the study.  
Research Question and Hypothesis 
RQ: Is there a significant predictive relationship between patient age, gender, 
insurance type, and race and the increased cost of radiation therapy associated with HPV-
related oropharyngeal cancer in Kentucky? 
Ha1:  There is no significant predictive relationship between patient age, gender, 
insurance type, and race and the increased cost of radiation therapy 
associated with HPV-related oropharyngeal cancer in Kentucky? 
Ho1:  There a significant predictive relationship between patient age, gender, 
insurance type, and race and the increased cost of radiation therapy 
associated with HPV-related oropharyngeal cancer in Kentucky? 
Threats to Validity 
A limitation was the number of variables available for this analysis. A potential 
threat to internal validity was the selection of variables and data collection. To reduce 
threats to statistical conclusion validity, a significance value of p < .05 was used to assess 
the association between variables. The reduction of threats was validated using SPSS. 
There was no threat to external validity. Data were collected from one regional Kentucky 




This study contains an analysis of a secondary dataset observing variable 
collected from the head and neck clinic at a regional cancer center. All participants are 
anonymous, and I had no direct contact with the participants in this study. IRB approval 
was obtained for this study from the University Medical Center on May 30, 2018, with 
the approval number of 18.0500. IRB approval was also given from Walden University 
on June 6, 2018, with the approval number of 06-04-18-0637405. 
Summary 
In this chapter, I explained the research design, rationale, and methodology of the 
study. The sampling and sampling procedures, data collection, secondary data 




Section 3: Presentation of the Findings and Results 
Introduction 
The purpose of this quantitative correlational research design was to evaluate the 
relationship between age, gender, race, insurance, and radiation therapy cost for HPV-
related oropharyngeal cancer in Kentucky. HPV has been linked to an increase in 
oropharyngeal cancers. A dataset covering the years 2010-2016 was collected from a 
head and neck cancer database. A review of literature revealed few studies assessing 
state-specific costs of treating HPV-related oropharyngeal cancer. 
Descriptive Statistics 
The study included four independent variables and one dependent variable.  The 
independent variables were patient gender, patient race, type of insurance for the patient, 
and age. Originally, the dependent variable was the cost difference, computed as the 
difference between the total cost for the patient and the estimated cost.  
Table 1 shows the gender of the patients. Of the 130 patients, most were male 
(83.1% male, 16.9% female). 
Table 1 
 
Frequency Table for Gender of Patient 
 
 Frequency Percent Valid percent 
Cumulative 
percent 
Valid Male 108 83.1 83.1 83.1 
Female 22 16.9 16.9 100.0 




Nearly three-fourths of all patients (74.8%) were covered by private insurance. 
Another 15.7% paid for treatment using Medicare or Medicaid, and 9.4% were covered 
by other government insurance (see Table 2).  
Table 2 
 
Frequency Table for Insurance Type Used by Patient 





Valid Medicare/Medicaid 20 15.4 15.7 15.7 
Private insurance 95 73.1 74.8 90.6 
Other government insurance 12 9.2 9.4 100.0 
Total 127 97.7 100.0  
Missing -1.00 3 2.3   
Total 130 100.0   
 
Table 3 shows that over 9 of 10 patients were White (91.5%); while (8.5%) were 
members of racial/ethnic minority groups. 
Table 3 
 
Frequency Table for Race of Patient 
 Frequency Percent Valid percent 
Cumulative 
percent 
Valid White 119 91.5 91.5 91.5 
Minority 11 8.5 8.5 100.0 
Total 130 100.0 100.0  
 






Frequency Table for Patient Age Group 





Valid Under 50 years old 13 10.0 10.0 10.0 
50 to 59 years old 55 42.3 42.3 52.3 
60 years and older 62 47.7 47.7 100.0 
Total 130 100.0 100.0  
 
Descriptive statistics for cost difference are listed in Table 5. The mean cost for 
radiation therapy treatment was $123,629.14 (SD = $58,697.36).   
Table 5 
 
Descriptive Statistics for Cost Difference Variable 
Variable                                      Value 
N Valid 129 
Missing 1 
Mean 123629.14 
Std. error of mean 5168.02 
Median 142376.00 
Std. deviation 58697.36 
Variance 3445379605.61 
Skewness -.60 
Std. error of skewness .21 
Kurtosis .58 










Figure 1 provides a boxplot of the cost difference dependent variable.  There was 
one outlier, and it was evident that the mean value was not part of a normal distribution.  
The boxplot provided evidence of the need to normalize the dependent variable using the 
z score of cost difference. 
 
Figure 1. Boxplot of cost difference. 
Another method to test the dataset for normality was to create a histogram and 
evaluate the skewness and kurtosis values associated with the frequency 
distribution/histogram (see Figure 2).  The histograms and skewness value indicated that 
the distribution for cost difference variable was slightly skewed to left. 
After the visual inspection of the distribution, the statistical method to test for 
normality of the dependent variable is the Kolmogorov-Smirnoff test (K-S) when the 




Figure 2. Histogram for cost difference. 
The z score for cost difference was developed because the distribution for cost 
difference was not normally distributed [K-S (129) = 0.215, p < 0.01] (see Table 6). 
Table 6 
 




Statistic df Sig. Statistic df Sig. 
Sum of charge—Total 
charge 
.239 129 .000 .856 129 .000 
Sum of estimated-
charge payments 
.192 129 .000 .802 129 .000 
Cost difference .215 129 .000 .881 129 .000 
aLilliefors significance correction. 
 
In Figure 3, the z score for cost difference appears normally distributed.  In the 




Figure 3. Histogram for z score of cost difference. 
Inferential Statistics: Testing the Hypotheses 
RQ. Is there a significant predictive relationship between patient gender, age, 
insurance type, and race and the increased patient cost associated with HPV-related 
oropharyngeal cancer in Kentucky? 
H01:  There is no significant predictive relationship between patient gender, age, 
insurance type, and race and the increased patient cost associated with 
HPV-related oropharyngeal cancer in Kentucky. 
Ha1:  There is a significant predictive relationship between patient gender, age, 
insurance type, and race and the increased patient cost associated with 
HPV-related oropharyngeal cancer in Kentucky. 
To test the hypotheses for the research question, a multiple regression was 
performed to predict the dependent variable z score of cost differences from a set of 
independent predictor variables for patient gender (male/female), patient age (under 
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50/50-65/over 65), type of insurance (Medicare-Medicaid/private insurance/other 
government insurance), and race (minority/White). 
There were 130 patients studied, with 127 valid responses without missing data.  
From Table 7, the dependent variable of z score of cost difference was normally 
distributed, with mean = 0 and standard deviation = 1.0. 
Table 7 
 
Descriptive Statistics of z Score of Cost Difference 
 
 Mean Std. deviation N 
z score of cost difference .0000 1.00000 127 
 
The residual results are shown in Figures 4-8.  These include a plot of normality, 
a scatterplot of the predicted and standardized residuals, and a histogram of the 
standardized residuals. Figure 4 presents a histogram of the residuals with a normal curve 
superimposed. The residuals appear close to normally distributed in Figure 5. The 
standardized residual plots show a random scatter of points with constant variability (see 
Figure 6 and 7). This was verified in Figure 8 with the linearity of the scatterplot.  In fact, 
the range of values predicted by the model was wide (minimum predicted value = -0.318, 




Figure 4. Histogram of z score of cost difference as dependent variable. 
  
 






Figure 6. Scatterplot of standardized predicted value by standardized residuals. 
  
 






Figure 8. Scatterplot of standardized residuals by z score of cost difference (dependent 
variable). 
 
A correlation matrix (see Table 8) was part of the multiple regression output so 
that preliminary issues with multicollinearity between independent predictor variables 
could be determined. Based on the correlations, it does not appear to be an issue.  
However, only the evaluation of tolerance values or VIF values can determine 
multicollinearity concerns in the final model. 
The multiple regression model was built using the Enter method for entering and 
removing variables from the equation.  The summary table (Table 9) indicated various 
diagnostic results for the multiple regression model including the coefficient of 
determination R2.  The coefficient of determination R2 demonstrates that only 3.1% of the 
change in the variance of the z score of cost difference can be explained by the 



































































































change df1 df2 
Sig. F 
change 
1 .176a .031 -.001 1.00044 .031 .972 4 122 .425 
 
Note. Predictors: (Constant), Recode age into groups, Gender, Insurance reduced to three categories, Race 




Table 10 indicates that the regression model was not statistically significant. The 
null hypothesis was accepted that the independent variables were not statistically 
significant predictors of the z Score of Cost Difference [F (4,122) = 0.972, p = 0.425]. 
Table 10 
 




squares df Mean square F Sig. 
1 Regression 3.892 4 .973 .972 .425a 
Residual 122.108 122 1.001   
Total 126.000 126    
Note. Predictors: (Constant), Recode age into groups, Gender, Insurance reduced to three 
categories, Race with two groups. 
 
The model coefficients and significance level for each of the independent 
variables are displayed in Table 11. There were no significant independent predictor 
variables (p > 0.05); gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378, p = 
0.171], insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230, p = 
0.818].  The model constant was also not statistically significant [t (127) =0.582, p = 
0.561].  The table also shows that the tolerance values are close to 1 and not near zero so 
there was no multicollinearity.  
The standardized regression coefficients () are used to express the relationship 
between each significant predictor variable and the dependent variable. The  values 














interval for B Collinearity statistics 




bound Tolerance VIF 
 (Constant) .382 .656  .582 .561 -.916 1.680   
Gender -.233 .247 -.087 -.943 .348 -.722 .256 .935 1.070 
Race  .465 .337 .131 1.378 .171 -.203 1.132 .876 1.141 
Insurance 
type 
-.279 .184 -.139 -1.512 .133 -.644 .086 .934 1.071 
Age 
group 
-.032 .137 -.021 -.230 .818 -.303 .240 .950 1.052 
 
A summary of the residuals that result from the predictor model are found in 
Table 12.  The value for the residuals (M = 0.00, SD = 0.984) relates to the low R2 value, 
the lack of predictability; however, it does show that the residuals are normally 





Multiple Regression Collinearity Table: z Score of Cost Difference as Dependent 
Variable 
 















1 1 4.770 1.000 .00 .00 .00 .00 .00 
2 .090 7.294 .00 .08 .10 .03 .53 
3 .081 7.662 .00 .64 .01 .26 .00 
4 .044 10.357 .00 .20 .72 .40 .02 




Multiple Regression Residuals: z Score of Cost Difference as Dependent Variable 
 
 Minimum Maximum Mean Std. deviation N 
Predicted value -.3178 .4573 .0000 .17574 127 
Residual -2.46661 3.45904 .00000 .98444 127 
Std. predicted value -1.808 2.602 .000 1.000 127 
Std. residual -2.466 3.458 .000 .984 127 
 
Gender was analyzed using an independent samples t-test to determine whether 
there was a significant difference in the mean z score for cost difference for between male 
and female patients.  First, Figure 9 was prepared to display an error bar plot of the mean 
z score of cost difference by gender of the patient. The error bar plot was used prior to the 
independent t-test as a preliminary determination of whether there was no difference in 
the means and variances between the two groups. The x-axis represents the two groups 
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from the independent variable (no/yes) and the y-axis represents the mean value of the 
dependent variable. 
In each error bar, the dot represents the mean of the group. The mean was read by 
placing a horizontal line across to the left to the y-axis and reading the value for that 
group.  The vertical distance between the two horizontal lines in each error bar was the 
variance.  
The closer in value the means the more likely the assumption of equal means will 
prove true when conducting the t-test.  The more similar the vertical distance between the 
horizontal bars for each group, the more likely Levene’s test of homogeneity of variance 
holds true.  From the error bar plot, it appears that the means are slightly different.  It also 
appears that the variance for the z score of cost difference in the female group was greater 
than in the male group.  It was thought that the independent t-test might show significant 
differences in means and variances. 
 
Figure 9. Error bar plot of mean z score of cost difference by gender. 
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Next, a table of summary descriptive statistics was constructed for the level of the 




Group Descriptive Statistics: z Score of Cost Difference by Patient Gender 
 
 Gender N Mean Std. deviation Std. error mean 
z score of cost 
difference 
Male 107 .0021 1.01976 .09858 
Female 22 -.2091 1.07738 .22970 
 
Table 15 presents the results from the Levene’s test of equal variances and the 
independent sample t-test for testing the null hypothesis that mean z score for cost 
difference for both male and female patients are equal. 
The Levene’s test of homogeneity of variance exhibits that there was no 
significant difference in the level of variance between male and female patients [F (127) 
=1.177, p = 0.280]. Therefore, equal variances are assumed.  Based on the results of the 
independent samples t-test in Table 15, there was no statistically significant difference in 
the mean z score of cost difference between male and female patients.  The null 










for equality of 
variances t test for equality of means 





difference Std. error difference 
95% confidence interval of 
the difference 
Lower Upper 













.845 29.253 .405 .21116 .24996 -.29988 .72219 
 
To test the hypotheses of age, a one-way ANOVA was constructed because there 
were three groups for patient age.  The dependent variable was the z score for cost 
differences in treatment.  First, an error bar plot was created. 
Figure 10 displays an error bar plot of the mean z score of cost difference by age 
group of the patient. An error bar plot was used prior to the independent t-test as a 
preliminary determination of whether there was no difference in the means and variances 
between the two groups.  From the error bar plot in Figure 10, it appeared that the mean z 
scores for cost difference were slightly different.  It also appears that the variance for the 
z score of cost difference in the under 50-year old group was greater than in the other two 
age groups.  We might expect that the independent t-test might show a significant 




Figure 10. Error bar plot of mean z score of cost difference by age group. 
Next, the one-way ANOVA provided a table of summary descriptive statistics for 
the level of the dependent variable for the three patient age groups.  These results were 





Group Descriptive Statistics: z Score of Cost Difference by Patient Age 
 N Mean Std. deviation Std. error 
95% confidence interval for mean 
Minimum Maximum Lower bound Upper bound 
Under 50 
years old 
13 .1660 1.07571 .29835 -.4841 .8160 -2.18 1.50 
50 to 59 54 -.0875 .99887 .13593 -.3602 .1851 -2.20 1.15 
60 years 
and older 
62 -.0291 1.05565 .13407 -.2972 .2390 -2.19 3.42 








   
.09105a -.4257a .3578a 
  
 
Levene’s test indicated the difference in the variation of z score cost differences 
based on age group was not statistically significant [F (2, 126) = 0.007, p = 0.993] (see 
Table 17). The one-way ANOVA assumption of equal variances held (see Table 18). 
Table 17 
 
Levene’s Test of Equal Variances: z Score of Cost Difference by Patient Age 
 
Levene 
statistic df1 df2 Sig. 
z score of cost 
difference 
Based on mean .007 2 126 .993 
Based on median .169 2 126 .845 
Based on median and with 
adjusted df 
.169 2 124.815 .845 




Table 18 indicated that the one-way ANOVA was not statistically significant and 
that there was no significant difference in the mean z score of cost differences based on 




one-way ANOVA Results for z Score of Cost Difference by Patient Age Group 
 Sum of squares df Mean square F 
Between groups (Combined) .676 2 .338 .316 
Linear term Unweighted .409 1 .409 .382 
Weighted .094 1 .094 .088 
Deviation .582 1 .582 .544 
Within groups 134.745 126 1.069  
Total 135.421 128   
 
This is also verified by the means plot in Figure 11. The effect size, calculated using eta 
squared which was calculated as the sum of squares between groups divided by total sum 





Figure 11. Means plots for z score of cost difference by patient age group. 
To test insurance type, a one-way ANOVA was constructed because there were 
three groups for patient insurance type.  The dependent variable was the z score for cost 
differences in treatment.  First, an error bar plot was created. 
Figure 12 displays an error bar plot of the mean z score of cost difference by the 
patient’s type of insurance. An error bar plot was used prior to the independent t-test as a 
preliminary determination of whether there was no difference in the means and variances 
between the two groups.  Evaluating Figure 12, it appeared that the mean z scores of cost 
difference were slightly different based on the patient’s insurance.  It also appears that the 
variance for the z score of cost difference for the other government insurance group was 
greater than for the private insurance or Medicare/Medicaid insurance groups.  We might 
expect that the independent t-test might show significant differences in variances but not 




Figure 12. Error bar plot of mean z score of cost difference by insurance type. 
The next table, Table 19, provided descriptive statistics for the z score of cost 
differences for each of the three types of patient insurance. 
Table 19 
 
Group Descriptive Statistics: z Score of Cost Difference by Patient Insurance Type 
 N Mean 
Std. 
deviation Std. error 
95% confidence interval for mean 
Lower bound Upper bound 
Medicare/Medicaid 20 .0342 1.00793 .22538 -.4375 .5059 
Private insurance 95 .0560 .96740 .09925 -.1411 .2531 
Other government insurance 12 -.5003 1.18330 .34159 -1.2521 .2515 
Total 127 .0000 1.00000 .08874 -.1756 .1756 
Model Fixed effects   .99464 .08826 -.1747 .1747 
Random effects    .15249 -.6561 .6561 
 
The one-way ANOVA assumption of equal variances held (see Table 20).  
Levene’s test indicated the difference in the variation of z score cost differences based on 





Levene’s Test of Equal Variances: z Score of Cost Difference by Patient Insurance Type 
 
Levene 
statistic df1 df2 Sig. 
z score of cost 
difference 
Based on mean 1.278 2 124 .282 
Based on median 1.417 2 124 .246 
Based on median and 
with adjusted df 
1.417 2 122.062 .246 
Based on trimmed 
mean 
1.344 2 124 .265 
 
Table 21 showed that the One-Way ANOVA was not statistically significant and 
that there was no significant difference in the mean z score of cost differences based on 
the patient’s type of insurance.  Therefore, the null hypothesis was accepted [F (2,126) 
=1.663, p = 0.191].   
Table 21 
 





square F Sig. 
Between 
groups 
(Combined) 3.325 2 1.663 1.680 .191 
Linear 
term 
Unweighted 2.143 1 2.143 2.166 .144 
Weighted 1.420 1 1.420 1.436 .233 
Deviation 1.905 1 1.905 1.925 .168 
Within groups 122.675 124 .989   
Total 126.000 126    
 
This is also verified by the means plot in Figure 13. The effect size, calculated 
using eta squared which was calculated as the sum of squares between groups divided by 
total sum of squares, was 0.03. According to Cohen (1988), there was only a small effect 




Figure 13. Means plots for z score of cost difference by patient insurance type. 
Race was analyzed using an independent samples t-test to determine whether 
there was a significant difference in the mean z score for cost difference based on patient 
race. Prior to this inferential test, Figure 14 was generated to provide an error bar plot of 
the mean z score of cost difference by race of the patient. An error bar plot was used prior 
to the independent t-test as a preliminary determination of whether there was no 
difference in the means and variances between the two groups.  From the error bar plot, it 
appears that the means for minority and white patients are slightly different.  It also 
appears that the variance for the z score of cost difference in the minority patient group 
was greater than in the white patient group.  We might expect that the independent t-test 




Figure 14. Error bar plot of mean z score of cost difference by race. 
Next, I provided a table of summary descriptive statistics for the level of the 




Group Descriptive Statistics: z Score of Cost Difference by Patient Race 
 





z score of cost 
difference 
White 118 -.0627 1.03491 .09527 
Minority 11 .2753 .94649 .28538 
 
Table 23 presents the results from the Levene’s test of equal variances and the 
independent sample t-test for testing the null hypothesis that mean z score for cost 
difference for both minority and white patients are equal. 
The Levene’s test of homogeneity of variance exhibits that there was no 
significant difference in the level of variance between minority and white patients [F 
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(127) = 0.256, p = 0.614].  Therefore, the assumption of homogeneity of variances holds.  
Based on the results of the independent samples t-test in Table 24, there was no 
statistically significant difference in the mean z score of cost difference between minority 
and white patients.  The null hypothesis was accepted [t (127) =--1.043, p = 0.299]. 
Table 23 
 




of variances t test for equality of means 
F Sig. t df 
Sig. (2-




interval of the 
difference 
Lower Upper 











-1.124 12.34 .283 -.338 .301 -.9916 .3154 
 
Summary 
The results presented in this quantitative retrospective study were an analysis of 
the head and neck dataset. A total population of 1654 cases of head and neck cancers was 
collected. Of the 1654 head and neck cancers, 628 were diagnosed with oropharyngeal 
cancer. Out of the 628 cases, 208 tested positive for HPV or p16. I used a multiple 
regression analysis to identify and evaluate the associations between the dependent and 
independent variables. The analysis revealed that the null hypothesis was accepted and 
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the alternate hypothesis was rejected. There was not a statistically significant relationship 
between cost and gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378, p = 0.171], 
insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230, p = 0.818]. 
Chapter 4 includes the interpretation, limitation, recommendations, implications for 
social change, and conclusions of the study. 
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Section 4: Application to Professional Practice and Implications for Social Change 
Introduction 
Human papillomavirus has been linked to an increase in oropharyngeal cancers. 
The cost associated with radiation therapy treatments for HPV-related oropharyngeal 
cancer is substantial. The purpose of this quantitative correlational research was to 
evaluate the relationship between age, gender, race, insurance, and radiation therapy cost 
for HPV-related oropharyngeal cancer in Kentucky. 
Concise Summary of Results 
I used secondary data from a regional cancer center to complete this study. The 
participants were selected from a head and neck cancer database for the period 2010 to 
2016. A total of 1,654 cases of head and neck cancers were collected; of the 1,654 head 
and neck cancers, 628 were diagnosed with oropharyngeal cancer. Out of the 628 cases, 
208 tested positive for HPV or p16. There were 130 patients studied, with 127 valid 
responses without missing data. The data were collected and analyzed using logistic 
regression, t test, and one-way ANOVA. The research question and hypotheses were 
developed to find any association between the dependent variable (cost) and independent 
variables (age, gender, race, and insurance). The null hypothesis was accepted, in that the 
independent variables were not statistically significant predictors of the z score of cost 
difference [F (4,122) = 0.972, p = 0.425]. The results showed no significant independent 
predictor variables (p > 0.05); gender [t (127) = -0.943, p = 0.348], race [t (127) = 1.378, 
p = 0.171], insurance type [t (127) = -1.512, p = 0.133], and age group [t (127) = -0.230, 
p = 0.818]). 
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Interpretation of the Findings 
Oropharyngeal cancer is the second most common HPV-associated cancer 
deserving attention for future interventions (CDC, 2017).  Research has demonstrated the 
cost of treating oropharyngeal cancer on a national level.  Little research has been 
completed on state-specific data. Kentucky’s population demonstrates a higher incidence 
of HPV-related oropharyngeal cancer compared to other states (CDC, 2017). 
The interpretations of the results were generated from a correlation matrix and 
multiple regressions to test the hypothesis concerning whether the independent variables 
were statistically significant predictors of cost difference for treatment. To test the 
hypotheses for the research question, a multiple regression was performed to predict 
values on the dependent or criterion variable, the z score of cost differences, from a set of 
independent predictor variables for patient gender (male/female), patient age (under 
50/50-65/over 65), type of insurance (Medicare-Medicaid/private insurance/other 
government insurance), and race (minority/White). 
Although the findings were not significant, previous literature demonstrated 
similar factors pertaining to HPV-related oropharyngeal cancer. This study showed that 9 
of 10 patients were aged under 50 (10%), 50 to 59 years old (42.3%), and 60 years and 
older (47.7%) compared to the median age of 57 years for HPV-positive patients in other 
studies (O’Sullivan et al., 2016). The NCI SEER population study examined data from 
2002 to 2012. The study concluded that patients under 60 years of age make up 59.2% of 
HPV-related cancers (Mourad et al., 2017). 
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Over 9 of 10 patients were White (91.5%), while (8.5%) were members of 
racial/ethnic minority groups. In a previous study, Cole et al. (2012) provided evidence 
that HPV-associated cancers disproportionately affect certain age, sex, and race/ethnicity 
groups. White men had the highest rate of cancers of the oral cavity, followed by Black 
men (CDC, 2017). Human papillomavirus oropharyngeal cancer affects Whites (21-64%) 
to a greater extent than Blacks (0-35%; (Rettig et al., 2015).  
SEER population study data for the period 2002 to 2012 indicated a male-to-
female ratio of 4:1 for HPV-related oropharyngeal cancer. A Portugal study reported an 
increase of 3.5 APC in men with oropharyngeal cancer (Mourad et al., 2017). Korea 
reported similar results, with an APC of 2.65% increase for men (Mourad et al., 2017). In 
contrast, a study in England found increases in incidence in men and women (47.1% and 
37.5%, respectively; Mourad et al., 2017). The percentage of HPV oropharyngeal cancer 
cases occurring in men has been reported as 65.8% in North America and 28.9% in Asia 
(Combes et al., 2017). In Asia, women had the highest incidence of HPV oropharyngeal 
cancer, representing 61.5% of cases. Of the 130 patients in this study, most were male 
(83.1% male, 16.9% female). 
Nearly three-fourths of all patients (74.8%) were covered by private insurance. 
Another 15.7% paid for treatment using Medicare or Medicaid, and 9.4% were covered 
by other government insurance. Kentucky ranks 18th in access to health care, and 9.8% of 
Kentucky’s population is uninsured (Bowling, 2016). From 2013 to 2014, approximately 
268,000 people gained coverage, increasing Medicaid coverage by 80%; the majority of 
these newly insured individuals were adults 19-64 years old (Yelowitz, 2016). A study 
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conducted on patients with neck cancer showed that Medicaid patients present with 
advanced cancer and higher rates of treatment delays compared to non-Medicaid patients 
(Naghavi et al., 2016). Oropharyngeal cancer treatment poses a significant cost for 
Medicaid, suggesting that early detection may reduce the economic burden of the disease. 
The mean cost for radiation therapy treatments in this study was $123,629.14 (SD 
= $58,697.36).  A review of 299 patients diagnosed with oropharyngeal cancer between 
2011 and 2015 revealed 72 patients available for evaluation to determine costs associated 
with treatment (Pinheiro & Krama, 2016). The average cost for radiation treatments was 
$83,222. A study in Texas found that the cost of treating oropharyngeal cancer was 
$106,604. The findings showed that the cost of care for oropharyngeal cancer was higher 
than in previous studies. The mean adjusted monthly health care cost for those with 
oropharyngeal cancer was $6,693 and $870 for those without cancer (Cavallo, 2017). 
Age, comorbidity, mental health, prediagnostic cost, and time were predictors of cost 
(Cavallo, 2017). A retrospective study consisting of 365 patients 20 years or older 
assessed median monthly costs as follows: diagnosis ($2,199), treatment ($4,161), end of 
life ($6,614), and total ($4,167; (Reveles et al., 2017). Costs were driven by outpatient 
costs (23%), inpatient costs (18%), and radiation therapy (16%; (Reveles et al., 2017). 
The findings of this study demonstrated that age, gender, race, and insurance do 
not influence the cost of radiation therapy treatments for HPV-related oropharyngeal 
cancer. The statistical analysis from this study demonstrated no relationship between the 
independent variables (age, gender, race, and insurance) and the dependent variable 
(cost). There were no significant independent predictor variables (p > 0.05); gender 
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[t(127 ) = -0.943, p=0.348], race [t(127 ) = 1.378, p=0.171], insurance type [t(127 ) = -
1.512, p=0.133], and age group [t(127 )= -0.230, p=0.818].  
Aday and Andersen’s (1974) theory may be used in explaining costs related to 
predisposing factors, enabling factors, and need factors. The independent variables for 
this study were the predisposing factors of age, race, gender, and HPV status; the 
enabling factor of insurance; and the needs factor of oropharyngeal cancer. The 
dependent variable was cost. The findings disconfirm the theory that cost is influenced by 
predisposing, enabling, and need factors.  
Limitations of the Study 
The objective of this study was to determine whether age, gender, race, and 
insurance affected radiation therapy costs associated with treating HPV-related 
oropharyngeal cancer. Some limitations of the study were the sample size, selection of 
variables, and data from one regional cancer center in Kentucky. A larger sample size, 
expansion of the sample to include additional facilities, and consideration of other factors 
such as alcohol and tobacco as casual factors in oropharyngeal cancer might have led to 
different results. Inclusion of these factors might have supported the findings by making 
it possible to generalize to a population outside the sample. 
Recommendations 
This retrospective study did not examine all factors that could lead to increased 
cost associated with treating HPV-related oropharyngeal cancer. Cancer staging and 
treatment cost for chemotherapy and surgery were not considered for this study. In the 
future, a study with a larger sample size representing other cancer centers in Kentucky 
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could be helpful in assessing the cost of radiation therapy treatments for HPV-related 
oropharyngeal cancer. In addition, future studies comparing smoking, alcohol, and HPV 
status among oropharyngeal cancer cases by gender, race, and age are recommended to 
help in understanding these risk factors. There is a need for future studies to evaluate all 
HPV-related cancers and the issue of HPV vaccinations. 
Implications for Professional Practice and Social Change 
Professional Practice 
Therapies used to treat oropharyngeal cancer can result in substantial cost to the 
healthcare system (Ward et al., 2016). Oral cancers that were commonly associated with 
older males and alcohol consumption are now affecting younger populations regardless 
of alcohol or tobacco use (OCF, 2017). HPV-positive cancers have a different clinical 
presentation compared to HPV-negative cancers. The treatment response and survival 
outcome have a favorable prognosis (Chung & Gillison, 2009). Understanding clinical 
behavior of HPV-positive cancers may improve disease prevention and strategies for 
head and neck cancer patients (Chung & Gillison, 2009).  Knowledge and experiences 
involving HPV vary across health professionals (Dodd, Foster, Waller, & Marlow, 2017). 
Addressing gaps in knowledge among health professionals may help with discussions and 
minimize negative psychosocial consequences of the disease. 
Social Change 
By 2020, cases of HPV oral pharyngeal squamous cell carcinoma are projected to 
outnumber HPV-mediated cervical cancer in the United States (Lewis et al., 2015). The 
importance of this finding involves the evaluation of HPV vaccination for prevention of 
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oropharyngeal cancer. From a health perspective, vaccinating boys has the potential to 
reduce the risk of HPV infection of sexual partners. Lowering HPV infection rates in the 
general population could lead to lower rates of HPV-related diseases for both genders 
(Lee & Garland, 2017). This study could contribute to positive social change by 
addressing HPV and the impact on health care costs associated with HPV-related disease. 
Conclusion 
This quantitative, correlational study examined whether age, gender, race, and 
insurance were associated with increased cost of radiation therapy treatments for HPV-
related oropharyngeal cancer. The results of the logistic regression showed no statistically 
significant correlation between age, gender, race, and insurance on radiation therapy cost. 
While this study did not show an association between these factors and cost, addressing 
human papillomavirus as a contributing factor in the increase of oropharyngeal cancers 
may promote the development of interventions for cancer prevention while reducing the 
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